Related Experiment Video

Updated: Jul 12, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K

The Promise and Limitations of Neoadjuvant Immune-Checkpoint Blockade in Resectable Non-Small Cell Lung Cancer

Alissa J Cooper1, Helena A Yu1

  • 1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

Cancer Discovery
|November 1, 2023
PubMed
Abstract

Insights

Neoadjuvant immune-checkpoint blockade shows promise for resectable non-small cell lung cancer. This study explored novel immunomodulatory agents before surgery, enabling biomarker research for future patient applications.

Area of Science:

  • Oncology
  • Immunotherapy
  • Translational Research

Background:

  • Neoadjuvant immune-checkpoint blockade is a rapidly evolving field for resectable non-small cell lung cancer (NSCLC).
  • Understanding the impact of novel immunomodulatory agents in the neoadjuvant setting is crucial.

Purpose of the Study:

  • To evaluate a platform study involving one cycle of novel immunomodulatory agents before surgical resection in NSCLC.
  • To facilitate translational biomarker studies within this neoadjuvant treatment paradigm.

Main Methods:

  • A platform study design was employed.
  • Patients with resectable non-small cell lung cancer received one cycle of novel immunomodulatory agents.
  • Translational biomarker analyses were conducted on resected tissue.

Main Results:

  • The study provided a unique opportunity for translational biomarker investigations.
  • Further research is needed to determine broader patient applicability.

Conclusions:

  • The neoadjuvant administration of novel immunomodulatory agents offers a platform for biomarker discovery in resectable NSCLC.
  • Questions remain regarding the optimal application and efficacy in a wider patient population.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533